Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.
Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder (…
US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM).
Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).
Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.
US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to Alzheimer’s disease (MCI due to AD).
The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat…
Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers.
Pharmaceutical Development Group (PDG) provides pharmaceutical regulatory consulting to firms located around the world.
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL).
Janssen Research & Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis.
Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment.
Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAFÉ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis (AD).
Cancer centres in Australia have launched a national clinical trial under the Zero Childhood Cancer programme to evaluate personalised medicine for childhood cancers.
US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea.
US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD).
Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2 diabetes.
US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme of TG-1101 (ublituximab) to treat patients with relapsing multiple sclerosis (RMS).
Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta…
inviCRO has completed the acquisition of UK-based translational research company Imanova.
Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share.
Tulane University in the US has reported positive results from a clinical trial of its new drug AQ-13, which is being developed for the treatment of malaria.
There are a number of sources of information that give a mathematical description of the terms used in light scattering. However, these will not usually give assistance in understanding their practical application.
GlaxoSmithKline (GSK) has reported positive results from two Phase III clinical trials of mepolizumab to treat patients with eosinophilic chronic obstructive pulmonary disease (COPD).
Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin’s lymphoma (NH…
US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid tumours.